Bridgend-based Molomix Bioscience raises £20k for multi-omics diagnostic platform

Molomix Bioscience Limited develops a decentralized, subscription-based platform designed for rapid molecular multi-omics diagnostics. Based in Bridgend, the company provides on-site genomic testing and pathogen detection services to healthcare providers, government health agencies, and research organisations across the United Kingdom and Europe.

The biotechnology firm recently raised £20k in a new funding round. This latest investment gives the company an estimated post-money valuation of £862k. According to official filings, the allotment of shares for this capital injection took place in September 2026.

Incorporated in 2020, the business focuses on connecting global health technology innovators with regional healthcare systems. It currently partners with SiGenex to deploy platforms that simplify the analysis of molecular substances for human, animal, and food-based pathogen detection.

Financial records for the year ended 30 November 2025 listed a single employee, though more recent data from LinkedIn indicates a headcount of seven staff members. Ronald Moody joined the board as a director in September 2026. AI-derived data suggests he may be linked to Investment Compliance.